This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Palvella Therapeutics to attend...
Business conference participation

Palvella Therapeutics to attend Goldman Sachs conference

Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of Coya Therapeutics' participation in a major healthcare conference could lead to increased investor awareness and potential interest in its stock. This event provides a platform for Coya Therapeutics to showcase its pipeline and strategy, which could positively influence its market valuation.

Biotechnology Pharmaceuticals
Event Summary

Coya Therapeutics, a clinical-stage biopharmaceutical company, announced that its Founder and CEO, Wes Kaupinen, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026. The company focuses on developing therapies for rare skin diseases and vascular malformations, with lead product candidates QTORIN™ rapamycin and QTORIN™ pitavastatin currently under development. A live webcast and archived replay of the fireside chat will be available on Coya Therapeutics' website.

Entities Involved
stock
Coya Therapeutics
Coya Therapeutics will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, providing an opportunity to present its pipeline and strategy to investors and potentially increase its visibility and investor interest.
Importance 100.0 Sentiment 10.0
per
Wes Kaupinen
Wes Kaupinen, Founder and CEO of Coya Therapeutics, will represent the company at the conference, leading the fireside chat.
Importance 80.0 Sentiment 10.0
stock
Goldman Sachs
Goldman Sachs is hosting the 47th Annual Global Healthcare Conference 2026, providing a platform for companies like Coya Therapeutics to engage with the investment community.
Importance 40.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is mentioned as the regulatory body whose approval is sought for Coya Therapeutics' therapies, highlighting the importance of regulatory milestones for the company's future.
Importance 20.0 Sentiment 0.0
Relationships
Goldman Sachs related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.